Fourth quarter 2017, compared to 2016, Group
- Gross order intake amounted to SEK 885,088 (626,306), an increase of 41,3%
- Order backlog amounted to SEK 893,014 (325,434), an increase of 174,4%
- 38% growth in orders for Episealer® knee implants during the quarter with 36 (26) approved orders
- Group net sales amounted to SEK 884,088 (1,007,759)
- Loss before tax amounted to SEK –15,547,283 (–18,454,211)
- Loss per share (weighted average) amounted to SEK –0.51 (–0.97)
Significant events during the fourth quarter
- Episealer® 24 months’ clinical study results accepted for publication in peer-reviewed scientific journal
- 5 years’ follow-up of the first Episealer® patient
- Episurf Medical reached milestone of 300 implants
- Episurf Medical obtained another new patent in China and Australia
- Fredrik Zetterberg appointed Head of Marketing for Episurf Medical
- Episurf Medical’s CEO Pål Ryfors acquired shares corresponding to 3.2% of capital and 6.8% of votes from main shareholder Serendipity Ixora
- Episurf Medical’s 100th Episealer® implant in Germany
Significant events after the fourth quarter
- Episurf Medical signed financing agreement of up to SEK 70m subject to approval at the general meeting
- Episurf Medical announced that the company is in the final stages of the development of an ankle implant
- Episurf Medical received market approval in Israel and signed distribution agreement for the Israeli market
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
